Results 151 to 160 of about 47,423 (289)

Research Progress of Psychological Intervention Combined with Phosphodiesterase-5 Inhibitors in the Treatment of Male Erectile Dysfunction

Zhai Jiawen, Shiyu Li, Chuntao Wang, Huaichun Zhou   +3 more
openalex   +2 more sources

Cytokine Milieu Relevant to Atopic Dermatitis Enhances Epidermal Trypsin‐Like Serine Protease Activity, Which Is Pharmacologically Suppressed in Human Keratinocytes

The Journal of Dermatology, EarlyView.
Shiori Onishi, Yohei Yasutomi, Onon Tsedendorj, Shin Morizane   +3 more
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Treatment With Phosphodiesterase 5 Inhibitors and Long-Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization. [PDF]

Catheter Cardiovasc Interv
Roy S, Min A, McFalls EO, Perera RA, Salloum FN, Jovin IS.   +5 more
europepmc   +1 more source

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease

David Greeley, Marshall Nash, Brad Herskowitz, Fred Kim, James Rock, Niels D. Prins, SangYun Kim, Tianyang Xi, Jonathan A. Busam, Benoit Tete, Jai Jun Choung, Sharon J. Sha   +11 more
openalex   +1 more source

Withdrawn: Effect of phosphodiesterase 5 inhibitors on the anti-tumor activity of poly-s-nitrosated human serum albumin

, 2015
Mayumi Ikeda, Yu Ishima, Ryo Kinoshita, Hiroshi Watanabe, Tsuyoshi Ikeda, Masaki Otagiri, Toru Maruyama   +6 more
openalex   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Exploring patient preferences regarding the use of combination therapy with endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitors (PDE5i). [PDF]

JHLT Open
Kolaitis NA, Kingman M, Wilson M, Rendon GG, Lopez D, Paoli CJ, Rahman M, Martin A, McGarvey N, Lee A, Mirza S, Melendres-Groves L.   +11 more
europepmc   +1 more source

Contribution of sewage to occurrence of phosphodiesterase-5 inhibitors in natural water. [PDF]

Sci Rep, 2021
Hong Y, Lee I, Tae B, Lee W, Pan SY, Snyder SW, Kim H.   +6 more
europepmc   +1 more source

VALIDATED LC-MS/MS METHOD FOR THE DETERMINATION OF TADALAFIL – A COMPETITIVE PHOSPHODIESTERASE 5 INHIBITOR (PDE5) – FROM HUMAN PLASMA

, 2019
Róbert Tőtős, József Balázsi
openalex   +1 more source